



ASX & MEDIA RELEASE

15 MAY 2018

MEDLAB COMPLETES THE FIRST SHIPMENT OF NANABIS™ TO ROYAL NORTH SHORE HOSPITAL (RNSH) AND COMMENCES ADVANCE CANCER PAIN HUMAN TRIAL

Medlab (ASX: MDC) is pleased to advise:

- Successful completion of the first shipment of NanaBis™ to Royal North Shore Hospital (RNSH)
- Medlab completes site initiation and subsequent trial on boarding at RNSH
- RNSH commences human trials in advance cancer pain utilising NanaBis™

Medlab is extremely pleased to announce trial commencement of NanaBis™, our cannabis-based medicine (CBD:THC) at RNSH for advance cancer pain.

Medlab's Managing Director, Dr Sean Hall commented, "This is what we have been working towards. It's a key milestone for the Company, we have a validated GMP Australian manufactured product that is being used in a robust and much-needed trial."

This trial will test the safety, efficacy and dose tolerance of cancer patients with both managed and unmanaged pain.

"We are very proud of our research collaboration with both Prof Stephen Clark and the team at RNSH, we are hoping that this trial demonstrates efficacious alternatives to opioid use for this type of patient." Dr Hall added.

The trial is expected to run over the next few months, with data available later in the year.

Dr Hall further commented, "all being well, this trial will form the basis of a NanaBis™ drug application being put before the TGA, and subsequent global regulatory agencies".

Medlab wishes to thank their loyal shareholders for support in achieving this significant milestone.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.